Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development

Premium

German biotech firm Kinaxo announced this week it has reached an agreement with AstraZeneca to use its mass spectrometry platform to investigate post-translational protein modifications in support of the drugmaker's oncology programs.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

Among Kinaxo's PTM-related products is its PhosphoScout service, which is designed to monitor the response of cellular signal transduction pathways to drug treatments. It also offers custom PTM analysis services and has struck deals with a variety of global pharma companies including Johnson & Johnson, Dalichi-Sankyo, Roche, and Bristol-Myers Squibb.

Kinaxo does its mass spec work on Thermo Fisher Scientific LTQ Orbitrap Velos machines.

Financial terms of the deal were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.